SOURCE: DNAPrint Genomics, Inc.

October 10, 2007 07:30 ET

DNAPrint Genomics to Present at Valuerich Small-Cap Financial Expo

SARASOTA, FL--(Marketwire - October 10, 2007) - DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Chief Executive Officer and President Richard Gabriel will present an overview of the Company to analysts at the ValueRich Small-Cap Financial Expo on Thursday, Oct. 18, 2007 at 1:35 p.m. eastern time. The expo will be held at the W New York Hotel, 541 Lexington Avenue in New York City.

During the 20-minute presentation, Mr. Gabriel will provide an overview of the Company and discuss its goals and outlook for the future. A webcast of the presentation will be available for 180 days after the show at http://www.ivaluerich.com/expo or on the Company's website at www.dnaprint.com.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941 366-3400
    -or-
    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848